**Supplementary table 1. Dose modification strategy for lenvatinib-related adverse events.**

|  |  |  |
| --- | --- | --- |
| **Treatment-related toxicity** | **Management** | **Dose adjustment** |
| Grade 1 or tolerable grade 2 | Continue treatment | No change |
| Intolerable grade 2 or grade 3 (first occurrence) | Interrupt lenvatinib until resolved to grades 0–1, or acceptable grade 2 | Reduce 4 mg lenvatinib |
| Intolerable grade 2 or grade 3 (second occurrence) | Interrupt lenvatinib until resolved to grade 0–1, or acceptable grade 2 | 1. Reduce to 4 mg lenvatinib per day for patients who were started at 12 mg  2. Reduce to 4 mg lenvatinib every other day for patients who were started at 8 mg. |
| Intolerable grade 2 or grade 3 (third occurrence) | Interrupt lenvatinib until resolved to grades 0–1, or acceptable grade 2 | 1. Reduce to 4 mg lenvatinib every other day for patients who were started at 12 mg.  2. Discontinue lenvatinib for patients who were started at 8 mg. |
| Intolerable grade 2 or 3 (fourth occurrence) | Interrupt lenvatinib until resolved to grades 0–1, or acceptable grade 2 | Discontinue lenvatinib |
| Grade 4 or thromboembolic event | Discontinue lenvatinib | Discontinue lenvatinib |

Grading according to CTCAE version 5.0.